Literature DB >> 17693391

Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia.

Malika Benbouzid1, Claire Gavériaux-Ruff, Ipek Yalcin, Elisabeth Waltisperger, Luc-Henri Tessier, André Muller, Brigitte L Kieffer, Marie José Freund-Mercier, Michel Barrot.   

Abstract

BACKGROUND: The therapeutic effect of antidepressant drugs against depression usually necessitates a chronic treatment. A large body of clinical evidence indicates that antidepressant drugs can also be highly effective against chronic neuropathic pain. However, the mechanism by which these drugs alleviate pain is still unclear.
METHODS: We used a murine model of neuropathic pain induced by sciatic nerve constriction to study the antiallodynic properties of a chronic treatment with the tricyclic antidepressants nortriptyline and amitriptyline. Using knockout and pharmacological approaches in mice, we determined the influence of delta-opioid receptors in the therapeutic action of chronic antidepressant treatment.
RESULTS: In our model, a chronic treatment by tricyclic antidepressant drugs totally suppresses the mechanical allodynia in neuropathic C57Bl/6J mice. This therapeutic effect can be acutely reversed by an injection of the delta-opioid receptor antagonist naltrindole. Moreover, the antiallodynic property of antidepressant treatment is absent in mice deficient for the delta-opioid receptor gene.
CONCLUSIONS: The antiallodynic effect of chronic antidepressant treatment is mediated by a recruitment of the endogenous opioid system acting through delta-opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17693391     DOI: 10.1016/j.biopsych.2007.06.016

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  26 in total

Review 1.  Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches.

Authors:  Claire Gavériaux-Ruff; Brigitte Lina Kieffer
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

2.  Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.

Authors:  Marta Peciña; Amy S B Bohnert; Magdalena Sikora; Erich T Avery; Scott A Langenecker; Brian J Mickey; Jon-Kar Zubieta
Journal:  JAMA Psychiatry       Date:  2015-11       Impact factor: 21.596

Review 3.  New treatments for chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Adam C Strauss; Jordan D Dimitrakov
Journal:  Nat Rev Urol       Date:  2010-02-09       Impact factor: 14.432

Review 4.  Conservative management of osteoporotic vertebral fractures: an update.

Authors:  A Slavici; M Rauschmann; C Fleege
Journal:  Eur J Trauma Emerg Surg       Date:  2016-12-26       Impact factor: 3.693

5.  Noise-induced hearing loss: Neuropathic pain via Ntrk1 signaling.

Authors:  Senthilvelan Manohar; Kimberly Dahar; Henry J Adler; Ding Dalian; Richard Salvi
Journal:  Mol Cell Neurosci       Date:  2016-07-26       Impact factor: 4.314

Review 6.  Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.

Authors:  Rafael Maldonado; Josep Eladi Baños; David Cabañero
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

Review 7.  The delta opioid receptor: an evolving target for the treatment of brain disorders.

Authors:  Amynah A Pradhan; Katia Befort; Chihiro Nozaki; Claire Gavériaux-Ruff; Brigitte L Kieffer
Journal:  Trends Pharmacol Sci       Date:  2011-09-17       Impact factor: 14.819

Review 8.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

9.  Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia.

Authors:  Yohann Bohren; Dzenan Karavelic; Luc-Henri Tessier; Ipek Yalcin; Claire Gavériaux-Ruff; Brigitte L Kieffer; Marie-José Freund-Mercier; Michel Barrot
Journal:  Eur J Pain       Date:  2009-12-28       Impact factor: 3.931

10.  Chronic curcumin treatment normalizes depression-like behaviors in mice with mononeuropathy: involvement of supraspinal serotonergic system and GABAA receptor.

Authors:  Xin Zhao; Chuang Wang; Jun-Fang Zhang; Li Liu; Ai-Ming Liu; Qing Ma; Wen-Hua Zhou; Ying Xu
Journal:  Psychopharmacology (Berl)       Date:  2013-12-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.